Lenz Therapeutics Stock Performance
| LENZ Stock | 35.50 1.18 3.44% |
On a scale of 0 to 100, LENZ Therapeutics holds a performance score of 14. The company secures a Beta (Market Risk) of 2.55, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, LENZ Therapeutics will likely underperform. Please check LENZ Therapeutics' value at risk, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether LENZ Therapeutics' current price movements will revert.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in LENZ Therapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, LENZ Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.44 | Five Day Return 6.48 | Year To Date Return 184.23 | Ten Year Return (59.46) | All Time Return (59.46) |
Forward Dividend Yield 0.8912 | Last Split Factor 1:7 | Dividend Date 2024-03-21 | Last Split Date 2024-03-22 |
1 | LENZ Therapeutics Insiders Up US178k On US551.1k Investment | 09/12/2024 |
2 | LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences | 09/30/2024 |
3 | Why LENZ Therapeutics Stock Hit A New 52-Week High Today | 10/21/2024 |
4 | LENZ Therapeutics Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partner... | 10/28/2024 |
5 | LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 | 10/30/2024 |
6 | LENZ Therapeutics, Inc. Q3 2024 Earnings Call Transcript | 11/07/2024 |
7 | LENZ Therapeutics to Present at 4 Major Healthcare Investor Conferences LENZ Stock News - StockTitan | 11/12/2024 |
8 | TANG CAPITAL MANAGEMENT LLC Expands Stake in LENZ Therapeutics Inc | 11/15/2024 |
9 | Heres Why LENZ Therapeutics, Inc. Is a Great Buy the Bottom Stock Now - MSN | 11/20/2024 |
| Begin Period Cash Flow | 47.7 M | |
| Free Cash Flow | -100.9 M |
LENZ |
LENZ Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,200 in LENZ Therapeutics on August 27, 2024 and sell it today you would earn a total of 1,350 from holding LENZ Therapeutics or generate 61.36% return on investment over 90 days. LENZ Therapeutics is currently generating 0.8553% in daily expected returns and assumes 4.647% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than LENZ, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
LENZ Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for LENZ Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as LENZ Therapeutics, and traders can use it to determine the average amount a LENZ Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1841
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LENZ | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.65 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.86 actual daily | 17 83% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average LENZ Therapeutics is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of LENZ Therapeutics by adding it to a well-diversified portfolio.
LENZ Therapeutics Fundamentals Growth
LENZ Stock prices reflect investors' perceptions of the future prospects and financial health of LENZ Therapeutics, and LENZ Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on LENZ Stock performance.
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.77 | ||||
| Current Valuation | 406.07 M | ||||
| Shares Outstanding | 27.47 M | ||||
| Price To Book | 3.11 X | ||||
| EBITDA | (122.24 M) | ||||
| Net Income | (124.65 M) | ||||
| Total Debt | 362 K | ||||
| Book Value Per Share | 7.46 X | ||||
| Cash Flow From Operations | (90.01 M) | ||||
| Earnings Per Share | (2.74) X | ||||
| Market Capitalization | 600.49 M | ||||
| Total Asset | 188.46 M | ||||
| Retained Earnings | (367.05 M) | ||||
About LENZ Therapeutics Performance
Evaluating LENZ Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if LENZ Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if LENZ Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (0.40) | (0.38) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (0.68) | (0.65) |
Things to note about LENZ Therapeutics performance evaluation
Checking the ongoing alerts about LENZ Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for LENZ Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| LENZ Therapeutics appears to be risky and price may revert if volatility continues | |
| LENZ Therapeutics was previously known as Graphite Bio and was traded on NASDAQ Exchange under the symbol GRPH. | |
| Net Loss for the year was (124.65 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| LENZ Therapeutics generates negative cash flow from operations | |
| LENZ Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Heres Why LENZ Therapeutics, Inc. Is a Great Buy the Bottom Stock Now - MSN |
- Analyzing LENZ Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether LENZ Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining LENZ Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating LENZ Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of LENZ Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of LENZ Therapeutics' stock. These opinions can provide insight into LENZ Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for LENZ Stock Analysis
When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.